Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03699267
Other study ID # 88/561
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 2015
Est. completion date June 2017

Study information

Verified date October 2018
Source Instituto Portugues de Oncologia, Francisco Gentil, Porto
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Ultrasound (US)-guided transversus abdominis plane block (TAP) has demonstrated favourable results in lower abdominal surgery. Literature about its efficacy in breast reconstruction surgery with transversus rectus abdominis myocutaneous (TRAM) flap is still scarce.

In the current study investigators pretend to evaluate the efficacy of US-guided bilateral TAP block for unilateral breast reconstruction using autologous abdominal graft in women with breast cancer's history.


Description:

The investigators led a prospective observational study in patients/participants scheduled to unilateral breast reconstruction surgery with TRAM flap (UBR TRAM) or partial/total or totalization mastectomy followed by TRAM reconstruction (M + UBR TRAM). Participants' anesthetic plan was general balanced anesthesia (GBA) or general balanced anesthesia combined with bilateral TAP block (GBA + TAP).

The anesthetic plan was adopted by the anaesthetist assigned to the operating room on surgery's day. Then, two groups were considered for the study: group submitted to GBA and another submitted to GBA + TAP. Anaesthetic information about intra-operative date was consulted. Investigators included patients subjected to general anesthesia with orotracheal intubation. Intravenous (IV) bolus of fentanyl were administered at anesthetic induction and according to analgesic needs. In patients whose anesthetic plan included TAP block investigators considered cases that it was performed after anesthetic induction before surgical incision. TAP block was performed according to Anesthesiology's Department. After aspiration, a volume of 20 mL ropivacaine 0.375% was administered, bilaterally. Investigators didn´t consider for the study participants whose systemic postoperative analgesic protocol wasn't that adopted by Anesthesiology Department for this kind of surgery.

It was evaluated:

- Intraoperative period: fentanyl consumption (mg/kg), antiemetic prophylaxis and anesthesia duration;

- Post-anaesthesia care unit (PACU): consumed opioids, total score and score relative to consciousness, at admission and discharge, pain assessment, at admission and discharge and nausea and vomiting incidence and stay's length

- After discharge of PACU until 4 hours after surgery's end and between 4th until 24th postoperative hour: morphine consumption, pain assessment, nausea and vomiting incidence and other complications.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients of age superior 18 years-old;

- Patients scheduled to unilateral breast reconstruction surgery with TRAM flap or partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan was GBA or GBA + TAP.

Exclusion Criteria:

- Refusal to participate in study;

- Inability to sign written informed consent;

- Body mass index superior (BMI) 40 kg/m2;

- Opioid tolerance (defined as previous consume, minimum period of 2 months, = 50 mg morphine equivalents, per os);

- Substance abuse (addiction syndrome)

- Renal chronic disease with creatinine clearance < 30 mL/min/1.73m2); hepatic disease (Child-Pugh score of 1, 2 or 3);

- Patients subjected to other surgeries within the same operative time

- Patients that TAP block was not performed before surgical incision and the dose and volume of ropivacaine wasn't 20 mL, ropivacaine 0.375%

- Patients whose systemic analgesic protocol wasn't that adopted by Anesthesiology Department for this kind of surgery

Study Design


Intervention

Other:
US-guided Bilateral TAP block


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Instituto Portugues de Oncologia, Francisco Gentil, Porto

Outcome

Type Measure Description Time frame Safety issue
Primary Fentanyl consumed/administered during intraoperative time Based on anaesthesia records, fentanyl administered during intraoperative time was calculated in milligrams per kilogram for each participant. Investigators recorded this variable for each participant since the date of start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
Primary Morphine consumed/administered during post-anaesthesia care unit stay Based on post-anaesthesia care unit records, quantity, in milligrams, of supplemental morphine administered to each participant was recorded. Investigators recorded this variable for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
Secondary Morphine consumed/administered after discharge from post-anaesthesia care unit discharge until 24 hours since surgery's end Based on records from Acute Pain Registration, it was recorded, for each participant, total morphine consumed/administered, in milligrams, since post-anaesthesia care unit's discharge until 4th postoperative hour and since 4th until 24th postoperative hour. Investigators recorded this variable for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
Secondary Pain's assessment at rest and on movement Evaluation of pain at rest and on movement, using a qualitative scale. Investigators used qualitative pain scale adopted in the study site. Scale ranges from 0 to 4. It is defined as: 0 - no pain reported by participant; 1 - slight pain reported by participant; 2 - moderate pain reported by participant; 3 - severe pain reported by participant and 4 - excruciating pain.
Pain assessment was recorded, based on records from post-anaesthesia care unit and Acute Pain Registration, for each participant at different moments. At admission and discharge from post-anaesthesia care unit, at 4th postoperative hour and at 24th postoperative hour.
Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
Secondary Recovery score, at admission and discharge from post-anaesthesia care unit, according to post-anaesthesia care unit's discharge criteria It was registered for each participant, total score at PACU's admission and discharge according to: Peripheral O2 saturation: 0 - < 85%, 1 - 85-95% and 2 - > 95%; Motor activity: 0 - inability to move, 1 - move 2 extremities; 2 - move 4 extremities; Hemodynamic: 0 - variation of medium arterial pressure (MAP) comparing to pre-anaesthetic evaluation > 40 mmHg or hear rate (HR)<40 or >50 bpm; 1 - variation of MAP comparing to pre-anaesthetic evaluation >40 mmHg or HR<50 or >120; 2 - MAP and HR similar to pre-anesthetic evaluation; Temperature: 0 - body temperature (T)<35ºC; 1 - T 35-35.5ºC; 2 - T 35.5-36ºC; Breathing: 0 - no spontaneous breathing; 1 - dyspnea/respiratory rate (RR) <10 or >20; 2 - eupnea; Consciousness: 0 - nor responding to stimuli; 1 - responding to simple questions; 2 - awake and alert; Nausea/Vomiting: 0 - vomiting; 1 - nausea; 2 - no nausea or vomiting; Pain: 0 - intolerable; 1 - intense; 2 - mild; 3 - no pain. Total score was calculated by summing each score. Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
Secondary Nausea and vomiting incidence Based on post-anaesthesia care unit and ward records, it was registered any episodes of nausea or vomiting for each participant until 24th postoperative hour. Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017).
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A